Electric fields for the treatment of glioblastoma

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Expert Review of Neurotherapeutics

• Publication date

  2012-10-01

• Fields of study

  Medicine, Engineering

• Identifiers
  DOI 10.1586/ern.12.112PMID 23082733
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma

  2012cited by this paper
• NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.

  2012cited by this paper
• Bevacizumab for the Treatment of Recurrent Glioblastoma

  2011cited by this paper
• End points for Phase II trials in recurrent glioblastoma: the cornerstone for a new era

  2011cited by this paper
• Scale to predict survival after surgery for recurrent glioblastoma multiforme.

  2010cited by this paper
• Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields)

  2009cited by this paper
• ‘Recurrent’ glioblastoma multiforme, when should we reoperate?

  2008cited by this paper
• Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas.

  2008cited by this paper
• Cost‐effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme

  2008cited by this paper
• Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme.

  2008cited by this paper
• The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme.

  2007cited by this paper
• Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors

  2007cited by this paper
• Surgical vs nonoperative treatment for lumbar disk herniation: the Spine Patient Outcomes Research Trial (SPORT) observational cohort.

  2006cited by this paper
• Recurrent glioblastoma multiforme: a review of natural history and management options.

  2006cited by this paper
• Glioblastoma Multiforme in the Elderly: A Therapeutic Challenge

  2005cited by this paper
• Phase II trial of gefitinib in recurrent glioblastoma.

  2004cited by this paper
• Disruption of cancer cell replication by alternating electric fields.

  2004cited by this paper
• Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme.

  2000cited by this paper
• A comparison of treatment results for recurrent malignant gliomas.

  2000cited by this paper

• Validation of Computational Simulation for Tumor-treating Fields with Homogeneous Phantom

  2022cites this paper
• Tumor-treating fields in combination with sorafenib restrain the proliferation of liver cancer in vitro.

  2022cites this paper
• Tumor-treating fields as a proton beam-sensitizer for glioblastoma therapy.

  2021cites this paper
• Tumor Treating Fields Therapy

  2020cites this paper
• Potential Applications of Static Magnetic Fields (SMFs) in Cancer Treatment

  2017cites this paper
• Virtual Human Models for Electromagnetic Studies and Their Applications

  2017cites this paper
• Tumor treating fields inhibit glioblastoma cell migration, invasion and angiogenesis

  2016cites this paper
• Modeling Tumor Treating fields (TTFields) application within a realistic human head model

  2015cites this paper
• The electric field distribution in the brain during TTFields therapy and its dependence on tissue dielectric properties and anatomy: a computational study

  2015cites this paper
• The effects of alternating electric fields in glioblastoma: current evidence on therapeutic mechanisms and clinical outcomes.

  2015cites this paper